---
title: "Cellectar Biosciences, Inc. (CLRB.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/CLRB.US.md"
symbol: "CLRB.US"
name: "Cellectar Biosciences, Inc."
industry: "Biotechnology"
---

# Cellectar Biosciences, Inc. (CLRB.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [www.cellectar.com](https://www.cellectar.com) |

## Company Profile

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company’s lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.74 | 165/605 | - | - | - |
| PB | 1.87 | 169/605 | 2.74 | 1.88 | 1.25 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-11-14T05:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 2 | 50% |
| Overweight | 0 | 0% |
| Hold | 2 | 50% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 3.12 |
| Highest Target | 76.00 |
| Lowest Target | 18.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/CLRB.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/CLRB.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/CLRB.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.